2-苯基-4-喹啉羧酸
中文名稱 | 2-苯基-4-喹啉羧酸 |
---|---|
中文同義詞 | 辛可芬;2-苯基-4-喹啉羧酸;2-苯基-4-喹啉羧酸,99%;2-苯基-4-喹啉甲酸;苯基金雞寧酸;喹苯甲酸;阿托方;2-苯基喹啉-4-羧酸 |
英文名稱 | CINCHOPHEN |
英文同義詞 | LABOTEST-BB LT00453769;RHEUMIN;RHEMATAN;2-PHENYLQUINOLINE-4-CARBOXYLIC ACID;2-PHENYLQUINOLEINE-4-CARBOXYLIC ACID;2-PHENYLCINCHONINIC ACID;2-PHENYL-4-QUINOLINECARBOXYLIC ACID;CINCHOPHEN |
CAS號 | 132-60-5 |
分子式 | C16H11NO2 |
分子量 | 249.26 |
EINECS號 | 205-067-1 |
相關(guān)類別 | 小分子抑制劑;ATOPHAN;API intermediates;Quinolinecarboxylic Acids, etc.;Quinolines |
Mol文件 | 132-60-5.mol |
結(jié)構(gòu)式 | ![]() |
2-苯基-4-喹啉羧酸 性質(zhì)
熔點 | 214-215 °C (lit.) |
---|---|
沸點 | 392.37°C (rough estimate) |
密度 | 1.1426 (rough estimate) |
折射率 | 1.5300 (estimate) |
儲存條件 | Keep in dark place,Sealed in dry,Room Temperature |
溶解度 | 酒精:1g溶于120ml(加熱) |
酸度系數(shù)(pKa) | 0.96±0.10(Predicted) |
形態(tài) | 固體 |
顏色 | 白色 |
水溶解性 | Insoluble in water |
敏感性 | Light Sensitive |
Merck | 14,2288 |
BRN | 192803 |
辛可芬的合成路線很多,將苯甲醛、苯胺和丙酮酸各一分子在乙醇溶液中加熱,可一鍋法制備得到?;蛞匀〈胚狨腿〈揭彝獮樵?無水乙醇為溶劑,在氫氧化鉀的存在下加熱反應(yīng)生成取代2-苯基-4-喹啉羧酸。2-苯基-4-喹啉羧酸的合成反應(yīng)式如下圖:
Cinchophen(2 - 苯基喹啉-4 - 羧酸)是一個功能強大的抗菌劑。 獸醫(yī)將Cinchophen和潑尼松龍組合使用,治療動物的關(guān)節(jié)炎。由于發(fā)現(xiàn)cinchophen會引起嚴(yán)重的肝損傷, 1930s停止了該藥在人體的使用。
Cinchophen (oral gavage; 25-44 mg/kg; twice daily) combines prednisolone ( 0.125-0.220 mg/kg; twice daily) for 14 days is effective in dogs with osteoarthritis and well tolerated. The combination exhibits significantly improved lameness, weight bearing, joint mobility and stiffness scores and is similar in clinical efficacy to phenylbutazone.The kinetics and efficacy of a cinchophen prednisolone combination preparation (PLT) is tested. Cinchophen administation at a dose rate of 12.5 mg/kg intravenously exhibits a volume of distribution (V d area) of 0.13 L/kg, shows a clearance rate (Cl) of 0.15 L/h and a half-life (t 1/2β ) of 7.92 hours. The plasma concentration time curve (AUC0-∞) is 1187.0 μ/ml.h in dogs. Cinchophen administation (oral gavage; 12.5 mg/kg; single dose) exhibits a mean maximum plasma concentration (C max ) of 77.75 μg/ml and the time of Cmax (t max ) is 2.76 hours. The plasma concentration time curve (AUC 0-∞ ) is almost as large following oral as intravenous administration indicating an oral bioavailability (F) of 87.21%.
安全信息
危險品標(biāo)志 | Xn |
---|---|
危險類別碼 | 22 |
安全說明 | 36/37/39-26 |
危險品運輸編號 | 3249 |
WGK Germany | 3 |
RTECS號 | GD4025000 |
危險等級 | 6.1(b) |
包裝類別 | III |
海關(guān)編碼 | 29334990 |
毒害物質(zhì)數(shù)據(jù) | 132-60-5(Hazardous Substances Data) |
毒性 | LD50 oral in dog: 1250mg/kg |
提供商 | 語言 |
---|---|
英文
|
|
英文
|
|
中文
|
|
英文
|